Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
07:05am, Wednesday, 05'th Nov 2025
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and oth
Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
07:00am, Wednesday, 05'th Nov 2025
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and ot
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
10:00am, Tuesday, 28'th Oct 2025
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
08:00am, Tuesday, 28'th Oct 2025
Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
10:00am, Thursday, 23'rd Oct 2025
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
10:00am, Saturday, 18'th Oct 2025
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
02:00pm, Monday, 13'th Oct 2025
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE
05:45pm, Wednesday, 08'th Oct 2025
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
12:36pm, Tuesday, 07'th Oct 2025
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
Skye Bioscience, Inc. - Special Call
02:25pm, Monday, 06'th Oct 2025
Skye Bioscience, Inc. - Special Call Company Participants Bernie Hertel Punit Dhillon - President, CEO, Secretary & Director Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Chri
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
01:09pm, Monday, 06'th Oct 2025
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 150 points on Monday.
Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss
10:39am, Monday, 06'th Oct 2025
Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab.
Skye Bioscience's obesity drug fails to meet main goal of mid-stage study
07:09am, Monday, 06'th Oct 2025
Skye Bioscience said on Monday its experimental obesity drug did not meet the main goal of a mid-stage study.
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
07:00am, Monday, 06'th Oct 2025
Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosin
Skye Bioscience: Promising Nimacimab Data Supports Buy Rating
10:45am, Wednesday, 01'st Oct 2025
Skye Bioscience is rated Buy, driven by nimacimab's strong safety, durable weight-loss profile, and upcoming Phase 2a results. SKYE's nimacimab targets the expanding anti-obesity market, showing poten
